Clinical trials: sponsored by Sichuan University
Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
Malnutrition is highly prevalent in patients with upper gastrointestinal tumors, which may negatively impact treatment tolerance and anti-tumor immune responses.
- Trial name
- INS-ESCC-CT (NCT07519486)
- Testing
- PD-1 Inhibitor plus Chemotherapy, Oral Enteral Nutritional Preparation, Esophagectomy with lymph node dissection
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Sichuan University
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This is an single-arm, multicenter phase II study to evaluate the safety and efficacy of Sacituzumab Tirumotecan (sac-TMT) plus anlotinib in previously treated extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- STAR-01 (NCT07501169)
- Testing
- Sacituzumab Tirumotecan and Anlotinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan University
Breast Feeding, Social Support
Effects of Spousal Participation in Breastfeeding Interventions at Different Perinatal Stages on Mothers' Coparenting Cognition and Infant Feeding Patterns
Problem: While partner support benefits breastfeeding outcomes, its impact across perinatal stages on maternal co-parenting perception is unclear.
- Conditions
- Breast Feeding, Social Support, Coparenting
- Trial name
- NCT07461038
- Testing
- Parental Involvement in Breastfeeding Support, Maternal-only Breastfeeding Support
- Where
- China
- Volunteers
- 526 people
- Sponsor
- Sichuan University
Small Cell Lung Cancer Extensive Stage
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined with Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
- Trial name
- SKY (NCT06610734)
- Testing
- Adebrelimab, Chemotherapy, low dose radiotherapy
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Sichuan University
Gastric Cancer, RCT
Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
The purpose of this clinical trial is to evaluate whether perioperative ivonescimab in combination with S-1 and oxaliplatin (SOX) is effective in treating locally advanced gastric or gastroesophageal junction (GEJ)…
- Trial name
- Huaxi (NCT07374250)
- Testing
- Ivonescimab (20mg/kg Q3W), Oxaliplatin, S-1
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sichuan University
Hematological Malignancies
Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection
At present, the treatment of multiple myeloma (MM) has evolved from traditional chemotherapy to a comprehensive model that includes targeted drugs, immunotherapy, etc.
- Trial name
- NCT07362732
- Testing
- WGb-0302 injection
- Volunteers
- 20 people
- Sponsor
- Sichuan University
B Cell Malignancies
Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection
Malignant hematological tumors mainly derived from adult B cells are mainly acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL).
- Trial name
- NCT07332663
- Testing
- WGb-0301 injection
- Volunteers
- 9 people
- Sponsor
- Sichuan University
Lung Cancer, Non-small Cell Lung Cancer
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer
This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.
- Trial name
- NCT06877299
- Testing
- Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Lung Squamous Cell Carcinoma
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
This is a randomized, controlled, open-label, multicenter phase II clinical trial comparing the efficacy and safety of low-dose radiation therapy and stereotactic body radiation therapy combined with PD-1 inhibitor (sintilimab)…
- Trial name
- NCT06121505
- Testing
- low-dose radiation therapy and stereotactic body radiation therapy, chemotherapy, Sintilimab
- Where
- 6 sites in China
- Volunteers
- 114 people
- Sponsor
- Sichuan University
Esophageal Cancer
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
This clinical trial is designed to evaluate the preliminary efficacy and safety of an oncolytic virus combined with chemotherapy and an immune checkpoint inhibitor in patients with initially unresectable, locally advanced…
- Trial name
- NCT07061704
- Testing
- Oncolytic Virus: Administered via intratumoral injection (metastatic lesions in the neck or supraclavicular lymph nodes) once every 3 weeks, for a total of two to four doses., Oncolytic Virus: Administered via intratumoral injection (primary lesions) once every 3 weeks, for a total of two to four doses.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Esophageal Cancer (EsC)
Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Trial
Symptom management is fundamental to clinical care, and symptom monitoring is an effective means to detect potential adverse events early and prevent serious complications.
- Trial name
- NCT07211009
- Testing
- Patient-Reported Outcome (PRO)-Based Symptom Management, Conventional Management
- Volunteers
- 240 people
- Sponsor
- Sichuan University
Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
This is a Phase I, open-label, dual-cohort clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of intratumoral injection of recombinant human endostatin adenovirus in combination with a PD-1…
- Trial name
- NCT07154108
- Testing
- recombinant human endostatin adenovirus, PD-1 Inhibitor
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Perioperative Respiratory Adverse Events, Adenoidectomy
Lateral Positioning for Extubation After Adenotonsillectomy
The postoperative recovery period following general anesthesia has been associated with a 30%-50% incidence of postoperative respiratory adverse events (PRAEs) in pediatric populations, including laryngospasm, airway obstruction…
- Conditions
- Perioperative Respiratory Adverse Events, Adenoidectomy, Tonsillectomy, Children
- Trial name
- NCT07108218
- Testing
- lateral postion, supine position
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Sichuan University
Neuroblastoma
Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
Radiopharmaceutical in Relapsed/Refractory Neuroblastoma
- Trial name
- NCT07067346
- Testing
- IR-101
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Sichuan University
Non-Small Cell Lung Cancer
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
This is a Phase II, open-labeled, single-arm, study of neoadjuvant BL-B01D1in combination with Almonertinib followed by adjuvant Almonertinib for the treatment of Patients with EGFR-Mutation Positive Stage II-IIIB Resectable…
- Trial name
- NCT06951464
- Testing
- BL-B01D1, Almonertinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Esophageal Cancer
The Intensive Nutritional Support in Esophageal Cancer Undergoing Neoadjuvant Therapy
Patients with esophageal cancer undergoing neoadjuvant therapy were selected as research subjects for nutritional risk screening and malnutrition assessment.
- Trial name
- INSECNT (NCT07067359)
- Testing
- Enteral Nutrition
- Volunteers
- 200 people
- Sponsor
- Sichuan University
Esophageal Squamous Cell Carcinoma (ESCC)
Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma
Patients with esophageal cancer still face a high risk of recurrence after receiving neoadjuvant chemoradiotherapy (nCRT) combined with radical surgery, especially for those who do not achieve pathological complete response…
- Trial name
- NCT07067450
- Testing
- Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab), Observation
- Volunteers
- 98 people
- Sponsor
- Sichuan University
Malignant Tumors
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
The goal of this study is to evaluate the safety and efficacy of mRNA vaccine for the KRAS mutation malignant tumors.
- Trial name
- NCT07004244
- Testing
- KRAS-mutated mRNA vaccine, TORIPALIMAB, Pemetrexed+carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Primary Central Nervous System Lymphoma (PCNSL)
High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma
The goal of this single-arm, prospective study is to learn if high dose gemcitabine, busulfan and thiotepa with autologous stem cell transplantation to treat primary or relapse central nervous system lymphomas.
- Trial name
- NCT07014943
- Testing
- High dose Gemcitabine, Busulfan, and Thiotepa as conditioning therapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sichuan University
Esophageal Squamous Cell Carcinoma
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
This study aims to investigate the efficacy and safety of low-dose radiation combined with neoadjuvant chemotherapy and immunotherapy in the treatment of locally advanced thoracic esophageal squamous cell carcinoma.
- Trial name
- NCT06446726
- Testing
- Tislelizumab, Low-dose radiotherapy, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University